April 25th 2024
With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Tivozanib Maintains PFS Benefit VS Sorafenib in R/R Renal Cell Carcinoma
November 6th 2022Results presented at the 2022 International Kidney Cancer Symposium show tivozanib continues to demonstrate progression-free survival benefit over sorafenib in relapsed or refractory renal cell carcinoma.
Read More
Lenvatinib/Pembrolizumab Upholds Efficacy Vs Sunitinib in Frontline Advanced RCC Vs Sunitinib
November 6th 2022After approximately 33 months of extended follow-up in the CLEAR study, investigators say lenvatinib plus pembrolizumab should be considered a standard of care option for frontline advanced renal cell carcinoma.
Read More
Need for Subsequent Therapy Limited With Lenvatinib/Pembrolizumab in Advanced RCC
November 5th 2022Subsequent therapy rates were lower in patients with advanced renal cell carcinoma treated with the combination of lenvatinib and pembrolizumab vs those who received sunitinib in the CLEAR trial.
Read More
Nivolumab Plus Ipilimumab Prolongs Survival in Treatment-Naïve Advanced Sarcomatoid RCC
November 5th 2022Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.
Read More
Doctors Debate: Should Upfront Therapy for RCC Consist of Doublets or Triplets?
November 4th 2022During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc
Read More
Discussing Tolerability of Tivozanib as Third-Line Therapy for mRCC
October 24th 2022During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed with participants their experience with the tolerability of tivozanib for recurrent advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Read More
Mao Discusses the Best Management Strategy for a Patient With Clear Cell RCC
October 23rd 2022During a tweet chat, Shifeng S. Mao, MD, PhD and Targeted Oncology Twitter followers discussed the case of 59-year-old woman with clear-cell renal cell carcinoma ad best treatment options for the patient.
Read More
ESMO 2022: New Combinations and Settings in RCC Show Mixed Results
October 19th 2022Following the success of immunotherapy-based therapy, investigators continue to explore new approaches for patients in a rapidly evolving field to continue to move the needle toward improved outcomes for patients with kidney cancer.
Read More